Verona Pharma plc

When clinical trial details are teased but deferred, investors will take a steer from the company management and key opinion leader commentaries. This has the potential for bias. Recent events around

Roivant has promised investors it will spend some of its impressive cash stockpile on buying new assets. But midway into the year, no deals have been signed. CEO Matt Gline, in an interview at the com

Stock market turmoil due to macroeconomic uncertainty and biopharmaceutical industry-specific concerns have made it more difficult for publicly traded drug developers to pursue follow-on public offeri

Financing of UK biotech companies nearly doubled in 2024 compared with the year before, with £3.5bn ($4.34bn) being raised to support new and existing companies. That represented a 94% increase in tot